Synthorx Stock Price - THOR

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Synthorx Inc THOR NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  1.43 6.65% 22.8772 24.15 21.5198 21.88 21.45 10:14:30
Bid Price Ask Price Spread Spread % News
22.60 22.88 0.28 1.22% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
690 60,885 $ 22.52 $ 1,371,323 100,516 11.00 - 24.15
Last Trade Time Type Quantity Stock Price Currency
10:14:30 5 $ 22.74 USD

Synthorx Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 720.81M 32.34M $ -56.61M -18.11 - 31.61M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 2.30%

more financials information »

Synthorx News

Loading Messages....

Latest THOR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical THOR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week18.2824.1516.8720.02287,8774.6025.15%
1 Month14.6424.1513.8818.17135,6898.2456.27%
3 Months19.0924.1511.0516.03103,4233.7919.84%
6 Months14.1824.1511.0515.6777,8318.7061.33%
1 Year15.4024.1511.0016.5997,9147.4848.55%
3 Years15.4024.1511.0016.5997,9147.4848.55%
5 Years15.4024.1511.0016.5997,9147.4848.55%

Synthorx Description

Synthorx Inc is a biopharmaceutical company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. The company through its platform technology expands the genetic code by adding a new DNA base pair. Its lead product candidate includes THOR-707 a variant of IL-2 designed to kill tumor cells. It uses the Expanded Genetic Alphabet platform technology to develop cytokine Synthorins. It has designed cytokine Synthorin programs, including IL-2, IL-10 and IL-15, for the treatment of cancer, and another IL-2 Synthorin program for the treatment of autoimmune disorders.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.